UGT1A1 and cancer: Although a recent meta-analysis was performed to analyze the difference in therapeutic response (TR) between IRI-administered cancer patients with different UGT1A1*28 genotypes [10], it only provided data on TR, a surrogate for the most important outcome: survival, and included studies of different cancers rather than completely focusing on patients with CRC.